News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
178,508 Results
Type
Article (17782)
Company Profile (22)
Press Release (160704)
Multimedia
Podcasts (20)
Webinars (3)
Section
Business (45726)
Career Advice (569)
Deals (6821)
Drug Delivery (29)
Drug Development (23124)
Employer Resources (35)
FDA (4016)
Job Trends (4015)
News (79380)
Policy (6897)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
Academia (1784)
Accelerated approval (5)
Adcomms (13)
Allergies (30)
Alliances (13965)
ALS (54)
Alzheimer's disease (602)
Antibody-drug conjugate (ADC) (78)
Approvals (4147)
Artificial intelligence (145)
Autoimmune disease (31)
Automation (7)
Bankruptcy (44)
Best Places to Work (3429)
BIOSECURE Act (15)
Biosimilars (63)
Biotechnology (12)
Bladder cancer (52)
Brain cancer (26)
Breast cancer (222)
Cancer (1610)
Cardiovascular disease (97)
Career advice (497)
Career pathing (7)
CAR-T (92)
CDC (10)
Cell therapy (211)
Cervical cancer (15)
Clinical research (19255)
Collaboration (486)
Compensation (105)
Complete response letters (11)
COVID-19 (1149)
CRISPR (31)
C-suite (202)
Cystic fibrosis (38)
Data (1843)
Denatured (3)
Depression (29)
Diabetes (125)
Diagnostics (1838)
Digital health (12)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (69)
Drug pricing (40)
Drug shortages (4)
Duchenne muscular dystrophy (39)
Earnings (12517)
Editorial (16)
Employer branding (6)
Employer resources (28)
Events (23493)
Executive appointments (224)
FDA (4882)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (6)
Frontotemporal dementia (13)
Funding (585)
Gene editing (57)
Generative AI (10)
Gene therapy (243)
GLP-1 (200)
Government (1420)
Grass and pollen (2)
Guidances (90)
Healthcare (5534)
HIV (18)
Huntington's disease (14)
IgA nephropathy (11)
Immunology and inflammation (73)
Immuno-oncology (17)
Indications (31)
Infectious disease (1225)
Inflammatory bowel disease (58)
Inflation Reduction Act (2)
Influenza (29)
Intellectual property (37)
Interviews (107)
IPO (3384)
IRA (13)
Job creations (729)
Job search strategy (413)
JPM (11)
Kidney cancer (9)
Labor market (29)
Layoffs (111)
Leadership (11)
Legal (1193)
Liver cancer (29)
Longevity (4)
Lung cancer (217)
Lymphoma (144)
Machine learning (12)
Management (10)
Manufacturing (163)
MASH (42)
Medical device (3016)
Medtech (3019)
Mergers & acquisitions (3774)
Metabolic disorders (269)
Multiple sclerosis (56)
NASH (7)
Neurodegenerative disease (89)
Neuropsychiatric disorders (20)
Neuroscience (979)
NextGen: Class of 2026 (1875)
Non-profit (2037)
Now hiring (7)
Obesity (98)
Opinion (88)
Ovarian cancer (59)
Pain (58)
Pancreatic cancer (62)
Parkinson's disease (84)
Partnered (11)
Patents (79)
Patient recruitment (139)
Peanut (12)
People (17176)
Pharmaceutical (8)
Pharmacy benefit managers (3)
Phase 1 (5947)
Phase 2 (8613)
Phase 3 (6550)
Pipeline (1391)
Policy (89)
Postmarket research (754)
Preclinical (2595)
Press Release (18)
Prostate cancer (78)
Psychedelics (13)
Radiopharmaceuticals (64)
Rare diseases (245)
Real estate (1359)
Recruiting (17)
Regulatory (5520)
Reports (11)
Research institute (1958)
Resumes & cover letters (91)
Rett syndrome (3)
RNA editing (4)
RSV (17)
Schizophrenia (47)
Series A (76)
Series B (56)
Sickle cell disease (30)
Special edition (3)
Spinal muscular atrophy (38)
Sponsored (4)
Startups (1227)
Stomach cancer (5)
Supply chain (25)
Tariffs (22)
The Weekly (17)
Vaccines (334)
Venture capital (41)
Weight loss (67)
Women's health (17)
Worklife (3)
Date
Today (33)
Last 7 days (146)
Last 30 days (530)
Last 365 days (7523)
2026 (711)
2025 (7650)
2024 (9131)
2023 (10575)
2022 (14004)
2021 (15321)
2020 (14402)
2019 (12940)
2018 (9760)
2017 (8755)
2016 (8804)
2015 (10233)
2014 (7596)
2013 (6140)
2012 (6250)
2011 (6486)
2010 (5521)
Location
Africa (277)
Alabama (56)
Alaska (3)
Arizona (78)
Arkansas (3)
Asia (10971)
Australia (2435)
California (2638)
Canada (693)
China (283)
Colorado (127)
Connecticut (134)
Delaware (120)
Europe (23833)
Florida (410)
Georgia (91)
Hawaii (1)
Idaho (14)
Illinois (277)
India (18)
Indiana (112)
Iowa (7)
Japan (138)
Kansas (23)
Kentucky (16)
Louisiana (6)
Maine (10)
Maryland (337)
Massachusetts (1798)
Michigan (58)
Minnesota (124)
Mississippi (1)
Missouri (38)
Montana (7)
Nebraska (4)
Nevada (13)
New Hampshire (15)
New Jersey (931)
New Mexico (7)
New York (979)
North Carolina (293)
North Dakota (3)
Northern California (1282)
Ohio (82)
Oklahoma (7)
Oregon (8)
Pennsylvania (520)
Puerto Rico (4)
Rhode Island (16)
South America (335)
South Carolina (11)
Southern California (1002)
Tennessee (67)
Texas (473)
United States (10009)
Utah (64)
Vermont (1)
Virginia (55)
Washington D.C. (38)
Washington State (230)
West Virginia (2)
Wisconsin (24)
178,508 Results for "doheny eye institute".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Doheny Eye Institute Announces Upcoming Presentations at the Association for Research in Vision and Ophthalmology 2025 Annual Meeting
April 16, 2025
·
4 min read
Biotech Beach
Doheny Eye Institute Announces Upcoming Presentations at ARVO 2024 Annual Meeting
Doheny Eye Institute announced that more than 25 of its scientists and clinician-scientists will present their latest research during the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, the premiere gathering for eye and vision scientists from across the globe.
April 24, 2024
·
3 min read
Press Releases
Doheny Eye Institute To Receive Funding from NIH Award Supporting Cerebral Small Vessel Disease Detection
October 3, 2024
·
6 min read
Gene therapy
AviadoBio Looks to China for Eye-Based Gene Therapy in $413M UgeneX Pact
AviadoBio will have the option to exclusively license UGX-202, a vision-restoring gene therapy for the rare eye condition retinitis pigmentosa.
October 10, 2025
·
2 min read
·
Tristan Manalac
Biotech Beach
Doheny Eye Institute Announces Upcoming Presentations at ARVO 2023 Annual Meeting
Doheny Eye Institute announced that more than 30 of its scientists and clinician-scientists will present their latest research during the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting. The meeting will take place April 23-27, 2023 in New Orleans at the Ernest N. Morial Convention Center.
April 21, 2023
·
3 min read
Gene therapy
Lilly Doubles Down on Eye Diseases, Adding to BD Spree
MeiraGTx Holdings is licensing a genetic eye disease medicine to Eli Lilly in a deal worth up to $475 million.
November 10, 2025
·
1 min read
·
Annalee Armstrong
Press Releases
Tenpoint Therapeutics Ltd. Announces FDA Approval of YUVEZZI™, the First and Only Combination Eye Drop Approved to Treat Presbyopia
January 29, 2026
·
8 min read
Business
Doheny Eye Institute Announces the Appointment of Deborah Ferrington, PhD as Chief Scientific Officer
Doheny Eye Institute, a global leader in vision research and basic science to save human eyesight, has announced that Deborah Ferrington, PhD, is joining the organization as Chief Scientific Officer.
January 12, 2022
·
2 min read
Immunology and inflammation
Lilly Eyes Pipeline in a Product as GLP-1s Move Into I&I
In addition to claiming revenue of $19.3 billion for the fourth quarter, Eli Lilly executives offered a glimpse into their strategy to expand their GLP-1 franchise into the immunology and inflammation space, with trials currently underway in asthma, psoriatic arthritis, Crohn’s disease and ulcerative colitis.
February 4, 2026
·
2 min read
·
Heather McKenzie
Deals
Boehringer Links with Irish Drug Delivery Start-Up Re-Vana in $1B+ Eye Deal
The German giant is looking to develop new drugs for undisclosed eye diseases using Re-Vana’s extended-release injectable platform to supply drugs to the eye for months at a time.
July 28, 2025
·
1 min read
·
Dan Samorodnitsky
1 of 17,851
Next
